Novartis Engineered Immune Cells Delay Cancer Advance in Study

Novartis AG’s experimental immune therapy delayed cancer progression in patients with advanced lymphoma in a study, boosting a new but unproven category of drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.